BIOMAT Database Logo BIOMAT Database Logo

Synthesis of potent and orally active HIV-protease inhibitors. 1996

H G Capraro, and G Bold, and A Fässler, and R Cozens, and T Klimkait, and J Lazdins, and J Mestan, and B Poncioni, and J L Rösel, and D Stover, and M Lang
Ciba-Geigy Ltd., Basel, Switzerland.

A series of potent HIV-protease inhibitors has been prepared. Several of the newly synthesized compounds showed high plasma even after oral administration to animals. Based on the overall biological profile, CGP 61755 was chosen for further preclinical evaluation. For this compound, a 10 step synthesis potentially suitable for large scale production was developed.

UI MeSH Term Description Entries
D012083 Renin A highly specific (Leu-Leu) endopeptidase that generates ANGIOTENSIN I from its precursor ANGIOTENSINOGEN, leading to a cascade of reactions which elevate BLOOD PRESSURE and increase sodium retention by the kidney in the RENIN-ANGIOTENSIN SYSTEM. The enzyme was formerly listed as EC 3.4.99.19. Angiotensin-Forming Enzyme,Angiotensinogenase,Big Renin,Cryorenin,Inactive Renin,Pre-Prorenin,Preprorenin,Prorenin,Angiotensin Forming Enzyme,Pre Prorenin,Renin, Big,Renin, Inactive
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular
D017320 HIV Protease Inhibitors Inhibitors of HIV PROTEASE, an enzyme required for production of proteins needed for viral assembly. HIV Protease Inhibitor,Inhibitor, HIV Protease,Inhibitors, HIV Protease,Protease Inhibitor, HIV,Protease Inhibitors, HIV

Related Publications

H G Capraro, and G Bold, and A Fässler, and R Cozens, and T Klimkait, and J Lazdins, and J Mestan, and B Poncioni, and J L Rösel, and D Stover, and M Lang
Orally bioavailable highly potent HIV protease inhibitors against PI-resistant virus.
December 2005, Bioorganic & medicinal chemistry letters,
H G Capraro, and G Bold, and A Fässler, and R Cozens, and T Klimkait, and J Lazdins, and J Mestan, and B Poncioni, and J L Rösel, and D Stover, and M Lang
Synthesis and evaluation of thiomannosides, potent and orally active FimH inhibitors.
September 2018, Bioorganic & medicinal chemistry letters,
H G Capraro, and G Bold, and A Fässler, and R Cozens, and T Klimkait, and J Lazdins, and J Mestan, and B Poncioni, and J L Rösel, and D Stover, and M Lang
New orally active serine protease inhibitors.
July 1995, Journal of medicinal chemistry,
H G Capraro, and G Bold, and A Fässler, and R Cozens, and T Klimkait, and J Lazdins, and J Mestan, and B Poncioni, and J L Rösel, and D Stover, and M Lang
Design and synthesis of potent, orally active, inhibitors of carboxypeptidase U (TAFIa).
March 2004, Bioorganic & medicinal chemistry,
H G Capraro, and G Bold, and A Fässler, and R Cozens, and T Klimkait, and J Lazdins, and J Mestan, and B Poncioni, and J L Rösel, and D Stover, and M Lang
Design and synthesis of potent, selective, and orally active fluorine-containing renin inhibitors.
January 1992, Journal of medicinal chemistry,
H G Capraro, and G Bold, and A Fässler, and R Cozens, and T Klimkait, and J Lazdins, and J Mestan, and B Poncioni, and J L Rösel, and D Stover, and M Lang
Structure-activity relationship of orally potent tripeptide-based HIV protease inhibitors containing hydroxymethylcarbonyl isostere.
September 2000, Chemical & pharmaceutical bulletin,
H G Capraro, and G Bold, and A Fässler, and R Cozens, and T Klimkait, and J Lazdins, and J Mestan, and B Poncioni, and J L Rösel, and D Stover, and M Lang
Potent HIV-1 Protease Inhibitors: Stereoselective Synthesis of a Dipeptide Mimic.
February 1993, The Journal of organic chemistry,
H G Capraro, and G Bold, and A Fässler, and R Cozens, and T Klimkait, and J Lazdins, and J Mestan, and B Poncioni, and J L Rösel, and D Stover, and M Lang
Oximinoarylsulfonamides as potent HIV protease inhibitors.
May 2005, Bioorganic & medicinal chemistry letters,
H G Capraro, and G Bold, and A Fässler, and R Cozens, and T Klimkait, and J Lazdins, and J Mestan, and B Poncioni, and J L Rösel, and D Stover, and M Lang
Nonpeptidic potent HIV-1 protease inhibitors.
April 1996, Drug design and discovery,
H G Capraro, and G Bold, and A Fässler, and R Cozens, and T Klimkait, and J Lazdins, and J Mestan, and B Poncioni, and J L Rösel, and D Stover, and M Lang
New series of potent, orally bioavailable, non-peptidic cyclic sulfones as HIV-1 protease inhibitors.
August 1996, Journal of medicinal chemistry,
Copied contents to your clipboard!